GlassScriptPhysician profile
Allison E Rolston
NPI 1316050586
$2,940.77
in general payments reported to CMS, 2019-2025
36 companies · $20.93 in 2025
The $20.93 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $927 · 2022: $1,240 · 2023: $710 · 2024: $42.61 · 2025: $20.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $539.97 | 2021-2023 | |
| Novo Nordisk INC | $337.79 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $281.47 | 2021-2023 | Repatha, Otezla, Prolia |
| Esperion Therapeutics, INC. | $215.83 | 2021-2022 | |
| Pfizer INC. | $198.15 | 2021-2023 | |
| Lilly USA, LLC | $174.83 | 2021-2023 | Mounjaro |
| Dexcom, INC. | $172.96 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $126.37 | 2021-2023 | |
| Ultragenyx Pharmaceutical INC. | $92.58 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $77.31 | 2023 | Rexulti |
| Boston Scientific Corporation | $65.81 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company LTD. | $63.05 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.39 | 2021-2022 | |
| Daiichi Sankyo INC. | $55.51 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $48.41 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $44.33 | 2022-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $40.86 | 2021 | |
| Abbott Laboratories | $36.22 | 2022-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $34.13 | 2021 | |
| Merck Sharp & Dohme LLC | $27.93 | 2021-2023 | Belsomra, Steglatro |
| Inspire Medical Systems, INC. | $25.29 | 2023 | Inspire |
| Alkermes, INC. | $21.90 | 2022 | |
| Astellas Pharma US INC | $20.30 | 2023 | Veozah |
| Amarin Pharma, INC. | $19.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.74 | 2022 | |
| Glaxosmithkline, LLC. | $15.67 | 2022 | |
| Halozyme INC | $15.42 | 2023 | |
| Sanofi Pasteur INC. | $13.50 | 2023 | |
| Sanofi-Aventis U.S. LLC | $13.31 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $12.65 | 2021 | |
| Philips North America LLC | $12.63 | 2022 | |
| Alexion Pharmaceuticals, INC. | $12.57 | 2022 | |
| Vistapharm, INC. | $12.38 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.74 | 2022 | |
| Qorumpartners | $11.60 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $11.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Rolston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.